EVP and head, Sanofi Genzyme
When Bill Sibold was promoted in July 2017 to head Sanofi Genzyme, Sanofi’s specialty care business unit, he became the first individual without ties to the “old,” pre-acquisition Genzyme to assume a top-shelf leadership position at the company. He was given a broad — and ambitious — charge: Essentially, to expand the unit’s purview from its traditional strength in conditions such as multiple sclerosis to include everything from multiple myeloma and squamous cell carcinoma treatments to drugs for Parkinson’s disease and asthma.
“We’re planning for growth,” he said at the time of his promotion, noting he would continue to emphasize the “two things that are core to Genzyme’s legacy — science and patients.”
As global head of Sanofi Genzyme’s MS, oncology, and immunology franchises, he oversaw the company’s launch of two new MS drugs. One of them, Aubagio, has succeeded to the extent Sanofi Genzyme now challenges longtime MS leader Biogen for category supremacy.